Table 1. Clinical data on patients with... | American Society of Hematology

Table 1.

Clinical data on patients with CD10⁺ or CD10⁻ B-precursor ALL

Case no.	Sex	Age at onset^*	Leukocyte count (per μL)	Percentage of blasts in peripheral blood^†	Karyotype	Positive immunological markers^‡
1	F	14 d	121 600	68	46XX,t(4;11;15)	19, 34, 45, 79a, HLA-DR
2	M	2 mo	257 000	93	46XY,t(4;11)(q21;q23)	15, 19, 34, 45, 79a, HLA-DR
3	M	2 y	67 900	87	46XY	10, 19, 33, 34, HLA-DR
4	M	2.2 y	159 000	90	63XXY	10, 19, 20, 34, 45, HLA-DR
5	M	1.5 y	388 000	88	46XY,t(11;12)(q13;q24)	10, 19, 34, 45, HLA-DR
6	M	9 y	6 500	30	46XY	10, 19, 20, 34, HLA-DR
7	M	2 y	2 300	0	46XY	10, 19, 20, 22, 34, HLA-DR

Case no.	Sex	Age at onset^*	Leukocyte count (per μL)	Percentage of blasts in peripheral blood^†	Karyotype	Positive immunological markers^‡
1	F	14 d	121 600	68	46XX,t(4;11;15)	19, 34, 45, 79a, HLA-DR
2	M	2 mo	257 000	93	46XY,t(4;11)(q21;q23)	15, 19, 34, 45, 79a, HLA-DR
3	M	2 y	67 900	87	46XY	10, 19, 33, 34, HLA-DR
4	M	2.2 y	159 000	90	63XXY	10, 19, 20, 34, 45, HLA-DR
5	M	1.5 y	388 000	88	46XY,t(11;12)(q13;q24)	10, 19, 34, 45, HLA-DR
6	M	9 y	6 500	30	46XY	10, 19, 20, 34, HLA-DR
7	M	2 y	2 300	0	46XY	10, 19, 20, 22, 34, HLA-DR

d indicates days; mo, months; y, years.

Case 7 had 98% lymphoblasts in 2 successive bone marrow aspirates.

An MLL fusion gene was demonstrated in cases 1 and 2 by Southern blot analysis (not shown).